Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
在 Ib/II 期临床试验 NCT02915432 中,评估了使用 PD-1 抗体 toripalimab 治疗化疗难治性胃癌的安全性、有效性和肿瘤突变负荷作为总生存获益生物标志物的可行性。
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdz197
Wang, F; Wei, X L; Wang, F H; Xu, N; Shen, L; Dai, G H; Yuan, X L; Chen, Y; Yang, S J; Shi, J H; Hu, X C; Lin, X Y; Zhang, Q Y; Feng, J F; Ba, Y; Liu, Y P; Li, W; Shu, Y Q; Jiang, Y; Li, Q; Wang, J W; Wu, H; Feng, H; Yao, S; Xu, R H